Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

SUNNYVALE, Calif., Nov. 10, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that innovations in hardware and software solutions and clinical data presented at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting continue to support the use of...

Accuray Showcases Radiation Therapy Innovations Designed to Enable Better Outcomes with Less Damage, Less Time, and Less Cost, at ASTRO 2020

Canon

LONDON--(BUSINESS WIRE)-- #GlobalHeadandNeckCancerDiagnosticsMarket--The Head and Neck Cancer Diagnostics Market will grow by USD 3.41 bn during 2020-2024

Head And Neck Cancer Diagnostics Market- Accuray Inc., Apteryx Imaging Inc., Canon Inc., Among Others to Contribute to the Market Growth | Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2024

Accuray (ARAY) registered growth in Service revenues in Q1.

Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates

Fiscal first quarter revenue was a little better than expected, and management did well on costs, achieving a modest profit where a modest loss had been expected. Orders were down, not surprising given the challenges/pressures from COVID-19, but the backlog remains significant and Accuray should start recognizing Type A system revenue in China this quarter.

Amid COVID-19 Pressures, Accuray Looks Toward The Start Of Its China Ramp

Accuray Incorporated (ARAY) CEO Josh Levine on Q1 2021 Results - Earnings Call Transcript

Accuray (ARAY) delivered earnings and revenue surprises of 100.00% and 10.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Break-Even Earnings for Q1

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Accuray (ARAY) Report Negative Earnings Next Week? What You Should Know

SUNNYVALE, Calif., Oct. 19, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Mike Leischer as its vice president and general manager, Americas (AMS) region, effective immediately. In this role, he will provide leadership of the AMS region...

Accuray Appoints Mike Leischer Vice President and General Manager, Americas Region

Cardinal Health

DaVita

These three MedTech stocks are expected to grow post their Q3 earnings release.

3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings

Intuitive Surgical

Stryker

Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.

Robot-Assisted Surgery Gains Momentum Amid Coronavirus

ABB Ltd.

AeroVironment

Brooks Automation

Raytheon Technologies

Robotics stocks represent innovation, technology and future profitability. For investors interested in those promises, click to read on.

7 Innovative Robotics Stocks to Buy For Future Profits

The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.

Accuray's Radixact With Synchrony Used in Japan Hospitals

SUNNYVALE, Calif., Sept. 17, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Japan are using the Radixact® System with the Synchrony® Automatic, Real-time Motion Synchronization Technology1 to provide advanced cancer treatments to more.

Accuray Radixact® System with Synchrony® Technology Delivers Advanced Cancer Treatments at Multiple Hospitals in Japan

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?

Accuray (ARAY) Down 16.5% Since Last Earnings Report: Can It Rebound?

SUNNYVALE, Calif., Sept. 10, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Joshua H.

Accuray to Present at Lake Street Capital Markets' 4th Annual Best Ideas Growth Conference

SUNNYVALE, Calif., Sept. 1, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at University Hospital Città della Salute e della Scienza, in Turin, Italy have treated the first cancer patients in the Europe, India, Middle East and Africa.

University Hospital Città della Salute e della Scienza, Turin, Italy is First in EIMEA to Treat Cancer Patients Using the Accuray Radixact® System with Synchrony® Technology

Accuray Idling On The Runway Ahead Of A Significant Chinese Revenue Launch

Accuray (ARAY) registered decline in Product and Service revenues in Q4

Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates

Accuray Incorporated (ARAY) CEO Joshua Levine on Q4 2020 Results - Earnings Call Transcript

Shares of Accuray (NASDAQ:ARAY) rose 1.66% in after-market trading after the company reported Q4 results.

Recap: Accuray Q4 Earnings

SUNNYVALE, Calif., Aug. 13, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2020.

Accuray Reports Fourth Quarter and Fiscal 2020 Financial Results

On Thursday, August 13, Accuray (NASDAQ: ARAY) will release its latest earnings report.

Accuray's Earnings Outlook

Accuray (ARAY) Earnings Expected to Grow: Should You Buy?

SUNNYVALE, Calif., July 22, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Anne B.

Anne B. Le Grand Joins Accuray Board of Directors

SUNNYVALE, Calif., July 16, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and the 2020 fiscal year, ended June 30, 2020 after the market close on Thursday, August 13, 2020.

News for Accuray Stock (ARAY)